Peptide dossier, updated Nov 1, 2026

CJC-1295

A 29-amino-acid synthetic analogue of growth hormone-releasing hormone, sold with and without a “DAC” add-on. FDA treats the version with the add-on (CJC-1295 DAC) and the version without as different substances. It has no approved use. FDA’s safety-risk page lists it among substances nominated for compounding and later withdrawn. This page lays out what each source actually says.

See all 10 verified records for CJC-1295 on the Records page

In plain terms

Approved for: Nothing. FDA has not approved CJC-1295 for any use, and no approved drug contains it.

What it is: A lab-made copy of the signal the brain sends to the pituitary gland telling it to release growth hormone. One version carries an added chemical piece meant to keep it in the blood longer.

What it is said to do, and by whom:

Sellers: FDA’s briefing says websites sell it as a “research use only” powder, alone and in blends with other growth-hormone-releasing peptides. We did not collect the sellers’ own claims.
The developer, ConjuChem: tested it in people with HIV-related abdominal fat in 2005–2006. The trial was terminated after a participant died. FDA says the data were never published.
Researchers: two 2006 papers in healthy adults reported prolonged rises in growth hormone and IGF-I levels.

How strong the evidence is: Thin. FDA counted 63 healthy adults exposed across the published human studies, and found no clinical effectiveness data for growth hormone deficiency, the use proposed in the nomination. No study we found shows a benefit for any condition.

FDA safety-risk page

Listed (withdrawn table)

FDA says it may pose immunogenicity risk for certain routes and has identified serious adverse events including increased heart rate and a systemic vasodilatory reaction. Clinical data are limited.

HHS enforcement, Oct 30

Not covered

The draft policy’s appendix names six covered peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. CJC-1295 is not one of them.

FDA advisory panel, Dec 2024

FDA proposed no listing

FDA’s briefing proposed that none of five CJC-1295-related substances be added to the 503A bulks list. We did not read the committee’s vote record. It was not among the seven peptides at the July 2026 meeting.

WADA prohibited list

Named

The 2026 list names CJC-1295 in section S2, growth hormone releasing factors. We read a copy of the list hosted by an athletics federation, because WADA’s own file would not open for us.

Human evidence

Small, healthy adults

One registered trial, terminated in 2006. Published human studies are short and in healthy adults.

Human studies

ClinicalTrials.gov returns one study for CJC-1295 as of Nov 1, 2026. It was terminated in 2006. The registry record does not give a reason.

Study	Sponsor	Status	What the record says
NCT00267527	ConjuChem (company)	Terminated; Dec 2005 to Sep 2006	Phase 2, placebo-controlled, in HIV patients with visceral obesity. The registry lists 120 enrolled. FDA’s briefing, citing a news report, says 192 were enrolled.

FDA’s briefing says a subject in this trial died of a heart attack after an 11th weekly dose, that the attending physician attributed it to undiagnosed coronary artery disease, and that the trial was terminated and its data never published. The briefing says no further information on other subjects or adverse events was available. Whether the company ended the trial for safety or other reasons is not stated in the documents we read. Registry entries are written by sponsors and are not reviewed for scientific merit.

FDA review

Two FDA documents address CJC-1295: the safety-risk page (content current Apr 22, 2026) and a briefing document for the Dec 4, 2024 advisory committee (memo dated Nov 15, 2024).

What FDA’s documents say

The safety-risk page lists CJC-1295 in the table of bulk substances nominated and later withdrawn, previously in category 2 under FDA’s interim policies.
It says compounded drugs containing it may pose immunogenicity risk for certain routes, may have complexities with peptide-related impurities and API characterization, and that FDA has identified serious adverse events, including increased heart rate and a systemic vasodilatory reaction. It says clinical data are limited.
The briefing evaluated five related substances: CJC-1295 (free base), its acetate, and three DAC forms. FDA proposed that none be added to the 503A bulks list, citing unclear characterization and naming, little information on historical compounding use, safety concerns in nonclinical studies, a lack of clinical safety data for all but one substance, and a lack of clinical effectiveness data for growth hormone deficiency.
The briefing found human studies only in healthy subjects: 63 adults, 87% men, most given one injection. Reported adverse events included injection-site reactions, flushing and transient hypotension, and a dose-dependent rise in heart rate.

What we did not find

We did not read the committee’s vote record from December 2024, so we do not state the tallies.
We found no FDA press release or drug safety communication specific to CJC-1295. Absence of one is not proven.
We found no FDA statement on what products sold online actually contain.

Sources: FDA briefing document, Nov 15, 2024 FDA: bulk substances that may present significant safety risks

Published research

PubMed returns 35 results for “CJC-1295” as of Nov 1, 2026. Many are doping-detection papers. The human studies are the two 2006 papers and a 2009 follow-up, all in healthy adults.

What the papers show

Healthy adults, 2006. Reports prolonged stimulation of growth hormone and IGF-I secretion after injection. J Clin Endocrinol Metab PubMed
Healthy adults, 2006. Reports that pulsatile growth hormone secretion persists during continuous stimulation. J Clin Endocrinol Metab PubMed
Healthy adults, 2009. Reports serum protein profile changes after activation of the growth hormone and IGF-1 axis. Growth Horm IGF Res PubMed
Rats, 2005. The paper describing the compound as a long-lasting growth hormone-releasing factor analogue. Endocrinology PubMed

Read with care

FDA’s briefing says the 2006 studies used CJC-1295 DAC in an unspecified form, and that its search found no study of any CJC-1295 form in a person with a disease other than the terminated trial.
We read titles and journal details only, not full text, funding or author affiliations. We did not check whether ConjuChem funded the human studies.
Rises in hormone levels are a laboratory measure. They are not evidence of a health benefit.

FDA warning letters

We found one FDA warning letter that names CJC 1295. It is addressed to a compounding pharmacy and is not a finding about CJC 1295’s safety. This rests on web searches, not a full pull of FDA’s database.

Recipient	Date	Letter	What it says
Tailor Made Compounding LLC, a compounding pharmacy	Apr 1, 2020	Warning letter 594743	FDA says an inspection found the firm compounding with a list of 22 bulk substances that includes CJC 1295, and that drugs made from them were not eligible for the section 503A exemptions. The letter says none of them is covered by a USP or NF monograph or is a component of an FDA-approved drug, and that the listed substances “have not been nominated” for the bulks list. We read the letter text.

A warning letter is FDA’s statement about one firm’s conduct on one date. It is not a finding about the substance. FDA’s list of letters cannot be searched by peptide, so other letters could exist that we did not find.

FDA recalls

FDA’s enforcement database (openFDA) returns four recalls of compounded products containing CJC-1295, all Class II, all for lack of assurance of sterility.

Firm	Recall number	Initiated	Reason
Assurance Infusion	D-0720-2020	Dec 20, 2019	Lack of sterility assurance
Advanced Nutriceuticals, LLC	D-0128-2021	Nov 30, 2020	Lack of assurance of sterility
Vita Pharmacy, LLC dba Talon Compounding Pharmacy	D-0109-2022	Oct 12, 2021	Lack of assurance of sterility
Thrive Health and Wellness, LLC dba Thrive Health Solutions (Colorado)	D-0475-2025	May 21, 2025	Lack of assurance of sterility

Source: openFDA enforcement data. A sterility recall is about how a firm made a product. It is not a finding about the substance. Some products were blends with other peptides.

Timeline

Newest first. Every entry links to the document it comes from.

Government or registry record
Journal

Oct 30, 2026Regulatory
HHS publishes draft policy pausing enforcement on six peptides; CJC-1295 is not one of them
The draft policy’s appendix names six peptides: BPC-157, TB-500, epitalon, Semax, KPV and MOTS-c. The policy is a draft and not FDA approval. We read the appendix through a text extraction, not the original PDF layout.
Federal Register Docket HHS policy appendix BakerHostetler summary
July 23–24, 2026Regulatory
FDA advisory committee meets on seven peptides; CJC-1295 is not among them
The committee recommended six of the seven, all nonbinding. FDA’s notice of the meeting does not list CJC-1295.
Federal Register notice Holland & Knight summary
Apr 22, 2026Regulatory
FDA’s safety-risk page lists CJC-1295
FDA lists it among substances nominated and later withdrawn, and cites immunogenicity risk, impurity and characterization complexities, serious adverse events and limited clinical data.
FDA page
Jan 1, 2026Anti-doping
WADA’s 2026 Prohibited List names CJC-1295 in section S2
The list names it among growth hormone releasing factors. We read a copy hosted by an athletics federation, not WADA’s own file.
WADA 2026 list (PDF)
May 21, 2025Enforcement
Recall of a compounded CJC-1295 product for lack of sterility assurance
The fourth of four recalls in FDA’s enforcement data. Class II.
openFDA
Dec 4, 2024Regulatory
FDA advisory committee reviews five CJC-1295-related substances; FDA proposed none be listed
FDA’s briefing says nominations from Wells Pharmacy Network and LDT Health Solutions were withdrawn and FDA evaluated the substances on its own initiative.
FDA briefing document
Apr 1, 2020Enforcement
FDA warning letter to a compounding pharmacy names CJC 1295 among 22 substances
The letter says drugs the firm compounded from these bulk substances were not eligible for the 503A exemptions.
Warning letter 594743
2009Literature
Serum protein changes after CJC-1295 in healthy adults
Published in Growth Horm IGF Res.
PubMed
2006Registry
Phase 2 trial in HIV visceral obesity is terminated after a participant dies
The registry lists the trial as terminated, Sep 2006. The death is described in FDA’s 2024 briefing, which cites a news report. The data were not published.
ClinicalTrials.gov FDA briefing
2006 Literature
Two studies in healthy adults report prolonged growth hormone and IGF-I stimulation
Published in J Clin Endocrinol Metab.
PubMed, March PubMed, December
2005Literature
First description of CJC-1295 as a long-lasting growth hormone-releasing factor analogue, in rats
Published in Endocrinology.
PubMed

Still not covered

Left off rather than guessed:

HHS policy: we read the draft policy appendix through a text extraction, not the original PDF layout. It names six covered peptides and not CJC-1295.
Advisory committee votes, Dec 2024: we read FDA’s briefing but not the committee’s transcript.
Why the 2006 trial ended: the documents we read describe the death and the termination but do not give the company’s reasoning.
WADA: read from a copy of the 2026 list, not WADA’s own file. We did not check other years.
Patents, SEC filings and ConjuChem’s own releases: not researched for this dossier.
Seller claims and independent lab reports: how it is marketed versus what testing finds. We have not collected testing data.
Unread items: full text of every paper; EU and other non-US registries and regulators; FDA warning letters other than the one listed, which rests on web searches.